Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.55 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.55 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.55 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CCR4 | P51679 | 1/20 | 0.40 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL256212 | 0.78 | PI4KA (0.47) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL30324182 | 0.77 | PI4KA (0.46) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL31175304 | 0.77 | PI4KA (0.46) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL20030782 | 0.77 | PI4KA (0.46) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL129887 | 0.77 | CCR4 (0.49) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL30303232 | 0.77 | CCR4 (0.49) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL2822778 | 0.77 | PI4KA (0.46) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL12536680 | 0.77 | PI4KA (0.46) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL23579575 | 0.77 | XDH (0.50) | CYP17A1CYP1A2MAPTNCF1 | |
| SCHEMBL14134413 | 0.77 | PIK3CD (0.42) | PI4KBCYP17A1CYP1A2KDM4ENCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| EP-4272832-A2 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Lakewood Amedex, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-11795192-B2 | Antimicrobial compounds, compositions, and uses thereof | Lakewood Amedex, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20210139522-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Lakewood Amedex, Inc. | 2021-05-13 | — | — | US | disclosed |
| US-9775841-B2 | Compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-03 | — | — | US | disclosed |
| US-20160318890-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2016-11-03 | — | — | US | disclosed |
| US-9018375-B2 | Substituted chromenes as kinase modulators | RHIZEN PHARMACEUTICALS SA (CH) | 2015-04-28 | — | — | US | disclosed |
| US-20140080827-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2014-03-20 | — | — | US | disclosed |
| US-8431366-B2 | Modified oligonucleotides and applications thereof | APPLIED BIOSYSTEMS, LLC (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-11-15 | — | — | US | disclosed |
| US-20110287431-A1 | MODIFIED OLIGONUCLEOTIDES AND APPLICATIONS THEREOF | Life Technologies Corporation (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | disclosed |
| US-7943752-B2 | Modified oligonucleotides and applications thereof | Applied Biosystems, L.L.C. (US) | 2011-05-17 | — | — | US | disclosed |
| US-20090226924-A1 | Modified Oligonucleotides and Applications Thereof | APPLERA CORPORATION | 2009-09-10 | — | — | US | disclosed |
| US-7524823-B2 | Macrolides | BASILEA PHARMACEUTICA AG (CH) | 2009-04-28 | — | — | US | disclosed |
| US-7517978-B1 | Modified oligonucleotides and applications thereof | APPLIED BIOSYSTEMS, LLC (US) | 2009-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226924-A1 | Modified Oligonucleotides and Applications Thereof | RNGTT, POLRMT, POLM | PI4KA 3213/4885PI4K2B 3410/4885PI4K2A 3413/4885 |
| US-20210139522-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CFTR, ABCB11, CEL | PI4KA 4058/4885PI4K2B 4352/4885PI4K2A 4328/4885 |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | PI4KA 82/4885PI4K2B 94/4885PI4K2A 95/4885 |
| US-20140080827-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | PI4KA 98/4885PI4K2B 82/4885PI4K2A 87/4885 |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | PI4KA 98/4885PI4K2B 82/4885PI4K2A 87/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | PI4KA 156/4885PI4K2B 140/4885PI4K2A 143/4885 |
| US-20160318890-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | PI4KA 98/4885PI4K2B 82/4885PI4K2A 87/4885 |
| US-11795192-B2 | Antimicrobial compounds, compositions, and uses thereof | CAT, MPO, NISCH | PI4KA 1930/4885PI4K2B 2372/4885PI4K2A 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.